Octreosphere (octreotide extended release)

Our findings revealed that immunohistochemistry allows specific detection of SSTR isoforms, whereas LDS could comprehensively evaluate SSTR expression. To the best of our knowledge, this is the first study to detect SSTR expression in breast cancer tissues using LDS, and the results suggest LDS as a new mode of evaluating SSTR status in clinical specimens.

Lymphangiogram with embolization is a safe and effective intervention for malignant chylothorax, regardless of surgical history. Early intervention can alleviate chyle leaks, facilitate ongoing cancer therapy, and improve patient outcomes, making it an important option in multidisciplinary oncology care.

UPR markers in FPitNETs are implicated as dominant A-UPR but blunted T-UPR. KIRA8, enhanced with octreotide, unbalances UPR, leading to anti-tumor effects. Targeting IRE1α may provide a novel strategy to treat PitNETs.

In scarred lesions, alternative resection strategies including free-hand EFTR with robust closure techniques may be considered. Improvements in OTSC design to prevent early dislodgement need to be considered in the future iterations of GD-FTRD.

Key inclusion criteria included a biochemical and clinical diagnosis of acromegaly due to a pituitary adenoma with persistent or recurrent disease, treatment with a stable dose of octreotide long-acting release or lanreotide Autogel for at least 3 months as monotherapy, and controlled disease with IGF-1 =1 x upper limit of normal (ULN). Key exclusion criteria included GH =2.5 µg/L at screening, pituitary surgery within 6 months of screening, prior pituitary irradiation, and recent treatment with pasireotide, pegvisomant, or dopamine agonists...Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*

In scarred lesions, alternative resection strategies including free-hand EFTR with robust closure techniques may be considered. Improvements in OTSC design to prevent early dislodgement need to be considered in the future iterations of GD-FTRD.

In uncontrolled patients with acromegaly, a trial with oral estrogen can be an option for young women. Oral estrogen was well tolerated, but the somatotropinoma that presented ER-α expression was the only somatotropinoma that presented growth during treatment.

Breast cancer may be an under-recognised MEN1-associated malignancy that presents at a younger age than in the general population with a relative risk of 2-3. Further research is required to determine the cost-effectiveness of breast cancer surveillance approach at a younger age in MEN1 patients relative to the general population .

This case illustrates the importance of following up on incidental radiographic findings and adds to the limited literature on sporadic UBPGLs, an uncommon, yet potentially life-threatening tumor. The diagnosis of these tumors is especially challenging when patients present with non-specific symptoms. Fortunately, in our case, the imaging study clued us into the possibility of a PGL.

All subjects received Sandostatin® (100μg immediate release; SIR) by deep SC injection 24h before MTD201... MTD201 (30mg) by either IM or SC injection produced continuous octreotide release over a period of at least 63 days at levels predicted to maintain efficacious plasma concentrations at steady state with a dosing interval of up to 8 weeks. Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.